1. Home
  2. DTSS vs BCAB Comparison

DTSS vs BCAB Comparison

Compare DTSS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Datasea Inc.

DTSS

Datasea Inc.

HOLD

Current Price

$0.84

Market Cap

9.0M

Sector

Technology

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$4.42

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTSS
BCAB
Founded
2014
2007
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0M
7.5M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
DTSS
BCAB
Price
$0.84
$4.42
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
87.6K
31.1K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
82.42
29.86
EPS
N/A
N/A
Revenue
$71,616,820.00
$300,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
198.70
N/A
52 Week Low
$0.64
$0.12
52 Week High
$2.60
$6.52

Technical Indicators

Market Signals
Indicator
DTSS
BCAB
Relative Strength Index (RSI) 41.12 55.02
Support Level $0.81 $0.36
Resistance Level $1.01 $6.33
Average True Range (ATR) 0.07 0.45
MACD -0.02 -0.16
Stochastic Oscillator 13.83 38.72

Price Performance

Historical Comparison
DTSS
BCAB

About DTSS Datasea Inc.

Datasea Inc is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Share on Social Networks: